evipedia.ai
← Back

Solubilized Keratin for Health & Longevity

Evidence Review created on 08/13/2026 using AI4L / Opus 5

Also known as: Soluble Keratin, Keratin Hydrolysate, Hydrolyzed Keratin, Functional Keratin, Cynatine HNS, Kera-Diet

Motivation

Keratin is the tough, sulfur-rich protein that hair fibres, nail plates and the outer layer of skin are built from. In its natural state it resists dissolving and digestion, which is why wool and feathers pass through the gut almost untouched. Solubilized keratin is keratin from sheep wool or poultry feathers that has been chemically or enzymatically pulled apart so the body can absorb it, then sold as a capsule or powder.

For most of the twentieth century wool and feather waste was burned or buried. Processing methods first built for wound dressings and cosmetics later made the same material edible, and by the 2010s branded keratin ingredients were being sold for hair thickness, nail hardness and skin smoothness. Interest has since widened past appearance, because keratin is unusually rich in a sulfur-containing building block the body also uses to make its main internal antioxidant.

This review examines what the published human evidence shows for solubilized keratin across hair, nail, skin and body-composition outcomes, who produced that evidence, what harms and interactions have been recorded, and how the supplement is used and monitored.

Benefits - Risks - Protocol - Conclusion

A short, curated set of high-level expert and academic sources that frame solubilized keratin, its therapeutic category of oral hair, nail and skin supplements, and the biology those products target.

No content naming keratin supplementation was found on foundmyfitness.com or lifespan.io, so neither priority platform appears above. Five qualifying sources were found, so the list is complete without padding.

Grokipedia

Keratin

Grokipedia’s primary keratin article covers structure, genetics and clinical significance of the protein family, but does not address oral solubilized keratin supplementation; no dedicated article on the supplement exists.

Examine

Keratin

Examine’s dedicated keratin page defines the protein class and its sources, and links a research feed tracking the trials of ingested keratin hydrolysates for skin, hair and nail outcomes.

ConsumerLab

ConsumerLab has published no dedicated review, article or product test of solubilized keratin. Its testing programme does not cover keratin supplements, so no product-level purity or label-accuracy data exists for this ingredient.

Systematic Reviews

These systematic reviews and meta-analyses (statistical pooling across studies) summarise the randomized controlled trial (RCT, where participants are randomly assigned to treatment or dummy) evidence for the oral hair, nail and skin supplement class solubilized keratin belongs to.

The claimed effect is covered above by Alanazi et al. and Nukaly et al., and the forgone benefit of choosing keratin over better-studied options by Zhou et al. and Sun et al. The harm side is covered only indirectly by Drake et al., because no systematic review or meta-analysis of keratin-specific harms, or of nail endpoints, has been published.

Mechanism of Action

Native keratin is a fibrous protein locked together by disulfide bonds (sulfur–sulfur cross-links) between cystine residues (pairs of the sulfur-containing amino acid cysteine, joined end to end). Those cross-links make hair, nail and wool insoluble and largely indigestible. Solubilization breaks them, either by sulfitolysis and controlled oxidation (chemical splitting of the sulfur–sulfur bridges, the route used for wool-derived ingredients) or by extensive enzymatic hydrolysis, which for feather-derived material yields a mixture that is at least 83.5% free amino acids (Tursi et al., 2025). That study, like almost all the human keratin evidence in this review, was manufacturer-funded.

Two mechanisms are proposed. The first is substrate supply: cysteine is the rate-limiting input both for new keratin assembled by keratinocytes (the cells that manufacture keratin) in the hair and nail matrix, and for glutathione, the body’s principal internal antioxidant, whose synthesis is capped by glutamate–cysteine ligase. Supporting this, hair cystine content rose 8.6% after 90 days of supplementation (Beer et al., 2014).

The second, “aminobiotic”, mechanism proposes that free amino-acid mixtures act as signals to skin cells rather than only as bricks, an interpretation its own authors advance cautiously (Tursi et al., 2025).

The competing explanation is that ingested keratin is digested indistinguishably from any other cysteine-rich protein, so effects reflect the co-formulated vitamins and minerals, not keratin. Solubilized keratin is a dietary protein, not a pharmacological compound, so it has no receptor selectivity, tissue distribution or enzyme-specific clearance; absorbed amino acids peak within roughly 30–120 minutes.

Historical Context & Evolution

Keratin’s first intended uses had nothing to do with swallowing it. Wool and poultry feathers were industrial waste, and the keratin extracted from them was developed through the twentieth century for textiles, then for biomaterials: wound dressings, films and hydrogels that exploit keratin’s ability to support cell migration. New Zealand groups working with sheep wool commercialised “functional keratin” for topical and wound-care use, and that lineage still runs: wool-derived keratin dressings were tested against venous leg ulcers (NCT02896725) and keratin grafts against diabetic foot ulcers.

Two observations moved it to the supplement aisle. First, keratin’s amino-acid profile is unusually rich in cysteine, the same residue that limits new hair and nail formation. Second, solubilization made a previously indigestible protein absorbable. Branded oral ingredients followed, and the first placebo-controlled human trials appeared in 2013 and 2014 for skin, hair and nail endpoints, with a joint-symptom trial alongside them (Beer et al., 2013).

The evolution since has been additive rather than corrective. No published work has retracted or overturned the early findings; instead, a second manufacturing lineage using poultry feathers produced a larger trial in 2025, and an independent sports-nutrition group found a lean-mass effect that the cosmetic literature had not looked for (Crum et al., 2018). What has changed is the standard applied: recent syntheses accept the direction of effect while pressing for independent replication, and that question remains genuinely open in both directions.

Expected Benefits

High 🟩 🟩 🟩

No benefit of solubilized keratin currently rests on high-quality evidence. Every human trial to date is small, short and, with one exception, funded or run by the company selling the ingredient, and no independent replication has been published.

Medium 🟩 🟩

Reduced Hair Shedding ⚠️ Conflicted

Fewer hairs are dislodged by a standardised pull test after three months. The proposed mechanism is a shift in the follicle cycle: both anagen (the active growing phase) and telogen (the resting phase before a hair is shed) improved by 9.2%. The evidence is one manufacturer-funded placebo-controlled trial in 50 women (Beer et al., 2014) plus a 2026 meta-analysis of 14 supplement trials that included this product. The conflict is real: that meta-analysis found growth-phase density improved but total hair count did not (Alanazi et al., 2026).

Magnitude: 34.4% fewer hairs shed on the pull test versus placebo at day 90 (46.6% versus each participant’s own baseline); pooled total hair count showed no significant change.

Improved Nail Hardness and Reduced Breakage

Nails become harder, less prone to splitting and less likely to break. Mechanistically, the nail plate is a keratin structure whose mechanical properties track its cystine cross-link density, so added cysteine plausibly reaches the nail matrix. Two placebo-controlled trials support this: hard nails rose from 37.5% to 87.5% of participants (Beer et al., 2014), and a three-arm trial in 99 women found dose-graded improvement (Tursi et al., 2025). Both were manufacturer-funded, and both relied partly on rater and self-assessment rather than instrumented hardness testing.

Magnitude: Participants reporting improved nail hardness reached 90.0% at 500 mg/day and 96.8% at 1000 mg/day by day 90, versus 27.6% on placebo.

Improved Skin Hydration, Elasticity and Wrinkle Depth

Facial skin holds more water, springs back better and shows shallower fine lines. The proposed mechanism is amino-acid supply to dermal fibroblasts plus a signalling effect on epidermal cells. The strongest data come from a 99-woman, three-arm, dose-ranging placebo-controlled trial using instrumented wrinkle-depth and skin-moisture measurement (Tursi et al., 2025), supported by an earlier 50-woman trial of the wool-derived ingredient (Beer et al., 2013). Both were sponsor-funded, in women only, and ran 90 days, so durability is unknown.

Magnitude: Deep skin moisturization +11.1% (500 mg) to +17.0% (1000 mg); wrinkle depth −9.4% to −12.0%; skin elasticity +5.8% to +7.6% at day 90 versus baseline, all significant against placebo.

Low 🟩

Increased Hair Fibre Strength and Cystine Content

Individual hair fibres resist breaking slightly better, and their measured cystine content rises, which is the most direct biochemical evidence that ingested keratin reaches the fibre. Evidence is a single manufacturer-funded trial, and the effect is small enough that its cosmetic relevance is unclear (Beer et al., 2014).

Magnitude: Hair tensile strength +5.9% and hair cystine content +8.6% at day 90 versus baseline, both significant against placebo.

Increased Lean Body Mass During Endurance Training

Used as a protein supplement, soluble keratin built more lean mass than an equal casein dose in trained cyclists, measured by dual-energy X-ray absorptiometry (a body-composition scan). This is the only independent trial, but it enrolled 15 men for four weeks and found no performance benefit (Crum et al., 2018).

Magnitude: +0.88 kg bone-free lean mass over four weeks versus +0.07 kg on casein; leg lean mass +0.45 kg from baseline.

Reduced Knee Osteoarthritis Symptoms

A joint-targeted keratin preparation halved knee pain scores relative to placebo over 60 days, with a similar effect on stiffness. Evidence is one manufacturer-funded trial of 50 adults using standard osteoarthritis symptom questionnaires, with no replication and no imaging or structural endpoint (Beer et al., 2013).

Magnitude: Roughly twice the placebo reduction in pain scores at 60 days; no absolute score change was reported for the between-group difference.

Speculative 🟨

Support for Glutathione Synthesis

Cysteine limits glutathione production, and glutathione falls with age, so a cysteine-dense protein is a plausible precursor. No keratin trial has measured glutathione; the basis is mechanistic, borrowed from cysteine-donor trials.

Intestinal and Epithelial Barrier Support

Free amino-acid keratin mixtures are being tested for effects on gut and skin cell behaviour rather than appearance. The basis is a mechanistic study design only, with no clinical endpoint measured and no results published.

Benefit-Modifying Factors

  • Baseline nail and hair quality: Benefit is largest where there is room to improve. Trials recruited women with visible signs of hair, nail and skin ageing; participants already at ceiling on hardness, gloss or shedding measures showed the smallest changes.

  • Ferritin and iron status: Ferritin (the blood measure of stored iron) below roughly 30 ng/mL is itself a cause of shedding. Correcting iron typically outperforms any supplement, and low iron will blunt an apparent keratin response.

  • Total protein and cysteine intake: At 500 mg, keratin adds a trivial share of daily cysteine. Someone eating 1.6 g/kg of mixed protein already receives many times that; benefit is more plausible in low-protein or restrictive diets.

  • Sex: Every cosmetic trial enrolled women only; the single lean-mass trial enrolled men only. Whether hair, nail and skin effects transfer to men is untested, and hormone-driven pattern hair loss in men has a different dominant driver.

  • Age: Follicle and nail matrix turnover slows with age, so visible change takes longer past 60. Trial populations spanned roughly 25–65, giving no data at the oldest end of a longevity-focused audience.

  • Genetic variation in keratin-associated proteins: Common variants in KRTAP genes, which encode the sulfur-rich proteins that cross-link the hair cortex, set how much cystine a fibre can incorporate and plausibly cap the achievable strength gain. This is untested for keratin supplements.

  • Cystine transport capacity: SLC7A11 encodes the transporter that imports cystine into cells for glutathione synthesis. Its expression is stress-inducible, so the antioxidant-precursor rationale should apply most where oxidative demand is already high.

  • Pre-existing conditions affecting hair and nails: Untreated thyroid disease, iron-deficiency anaemia, autoimmune hair loss and fungal nail infection all suppress response. Addressing them first changes both the achievable benefit and the correct interpretation of any change seen.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk of solubilized keratin rests on high-quality evidence. Trials to date are too small and too short to detect anything beyond common, mild events, and no post-marketing surveillance dataset specific to keratin supplements exists.

Medium 🟥 🟥

Laboratory Test Interference from Co-Formulated Biotin

The best-studied branded keratin capsule is sold with biotin, and biotin at supplement doses distorts many immunoassays (laboratory tests that use antibodies to detect a target). Depending on assay design, results can read falsely high or falsely low, which matters most for thyroid-stimulating hormone and for troponin, the marker used to diagnose heart attacks. This is well replicated in analytical studies (Li et al., 2018) and is a property of the formulation rather than of keratin itself.

Magnitude: Clinically significant interference is documented once circulating biotin exceeds roughly 10 ng/mL, a level reached within hours of a single 10 mg dose; direction and size of the error vary by assay platform.

Low 🟥

Gastrointestinal Intolerance

Mild digestive complaints are the most commonly recorded event. In the wool-derived trial, one participant on active product withdrew claiming intolerance, judged individual susceptibility rather than a product effect (Beer et al., 2014). The feather-derived trial recorded intestinal complaints among dropouts, attributed to seasonal illness (Tursi et al., 2025).

Magnitude: 1 of 25 participants (4%) withdrew from the active arm for claimed intolerance; overall tolerability was rated good or excellent by every completer.

Allergic Reaction to Animal-Derived Protein

Solubilized keratin comes from sheep wool or poultry feathers, and combination products routinely add marine collagen. A biotin-collagen-keratin capsule was recalled in 2021 for an undeclared fish allergen. Trials excluded known keratin or amino-acid allergy, so incidence in unselected users is unmeasured (Tursi et al., 2025).

Magnitude: Not quantified in available studies. No controlled trial has enrolled allergic participants, and no surveillance system tracks reactions to keratin supplements specifically.

Mineral Overload from Multi-Ingredient Formulas

Branded keratin capsules bundle zinc, copper, selenium and B vitamins, and users often stack them with a multivitamin. Sustained zinc above roughly 40 mg/day depletes copper, and selenium above 400 µg/day causes hair and nail loss, the opposite of the intended effect (Sechi et al., 2025).

Magnitude: Tolerable upper intake levels of 40 mg/day for zinc and 400 µg/day for selenium in adults; stacked hair, skin and nail products can approach or exceed these before food is counted.

Delayed Evaluation of a Treatable Cause

Shedding and brittle nails are common presentations of iron deficiency, thyroid disease, autoimmune hair loss and fungal nail infection. Because a keratin supplement is easy to obtain and produces gradual, partly subjective change, it can absorb the months during which a diagnosable cause goes unassessed (Drake et al., 2023).

Magnitude: Not quantified in available studies. No trial has measured diagnostic delay, because supplement trials screen out participants with an identified underlying cause before randomisation.

Speculative 🟨

Sulfur Amino Acid Load and Longevity Signalling

Restricting methionine and cysteine extends rodent lifespan through nutrient-sensing pathways. At 500 mg the added load is trivial; at protein-supplement doses it is not. No human outcome data exist (Lee et al., 2016).

Contaminant Carry-Over from Animal Source Material

Wool and feathers concentrate environmental metals, and processing uses oxidising and sulfiting agents. Residue specifications are undisclosed for most products. The basis is mechanistic reasoning about source material, with no measured contamination reported.

Risk-Modifying Factors

  • Biotin sensitivity of the testing pathway: Anyone whose laboratory uses older biotin-streptavidin immunoassays, or who presents acutely with chest pain, faces a materially larger risk from co-formulated biotin than someone monitored on newer, interference-resistant platforms.

  • Baseline zinc, copper and selenium status: Users already replete, or taking a multivitamin and a separate hair product, are the ones who cross upper intake limits. Measured baseline levels change the risk from theoretical to actionable.

  • Sex: Cosmetic trials enrolled only women and the lean-mass trial only men, so sex-specific harms are undescribed for both. Women of childbearing age also face untested exposure, since pregnancy and lactation were exclusion criteria throughout.

  • Kidney and liver function: Amino-acid loads at protein-supplement doses raise nitrogen handling demands. Advanced chronic kidney disease, roughly an estimated glomerular filtration rate (a calculated measure of kidney filtering capacity) below 30, shifts this from irrelevant to relevant.

  • Age: Older users take more medications, have more borderline kidney function and a higher likelihood of a cardiac or thyroid workup where biotin interference matters. Trials enrolled few participants past 65, so this group is least characterised.

  • Inherited sulfur-metabolism variants: Cystathionine beta-synthase deficiency, the enzyme defect behind homocystinuria, alters handling of sulfur amino acids. Phenylketonuria (an inherited inability to break down the amino acid phenylalanine) matters separately, because free amino-acid keratin hydrolysates contain unbound phenylalanine.

  • Atopic and food-allergy history: Prior reaction to wool, lanolin, poultry protein, fish or shellfish raises the chance of reacting either to the keratin source or to collagen and marine ingredients bundled with it in combination products.

Key Interactions & Contraindications

  • Biotin-containing formulations and immunoassays: Caution. Co-formulated biotin distorts antibody-based blood tests, including thyroid-stimulating hormone and troponin. Mitigation: stop the product 48–72 hours before any blood draw and tell the laboratory (Li et al., 2018).

  • Levothyroxine: Caution. Zinc and copper in combination keratin capsules bind thyroid hormone tablets and reduce absorption, risking undertreatment. Mitigation: separate the two by at least four hours and recheck thyroid function after eight weeks.

  • Tetracycline and fluoroquinolone antibiotics (doxycycline, minocycline, ciprofloxacin, levofloxacin): Caution. Divalent minerals chelate these drugs and can cause treatment failure. Mitigation: separate dosing by at least two hours before or four hours after the antibiotic.

  • Bisphosphonates (alendronate, risedronate) and penicillamine: Caution. Mineral co-ingredients markedly reduce absorption of both. Mitigation: take the drug fasting on waking and delay the keratin product by at least 60 minutes for bisphosphonates, four hours for penicillamine.

  • Over-the-counter antacids and mineral supplements (calcium carbonate, magnesium hydroxide, iron salts): Caution. Competing divalent cations reduce zinc and copper uptake from the capsule, blunting the formulation rather than causing harm. Mitigation: separate by two hours.

  • Additive supplement interactions — zinc, selenium and multivitamins: Caution. Stacking hair, skin and nail products with a multivitamin duplicates the same minerals and can exceed upper intake limits, causing copper depletion or selenium-induced hair and nail shedding. Mitigation: total the labels.

  • Additive sulfur amino acid sources — N-acetylcysteine, whey protein, collagen peptides, methylsulfonylmethane: Caution. These stack cysteine and sulfur load with keratin. No clinical consequence is documented at cosmetic doses; relevance rises at protein-supplement doses. Mitigation: count total daily protein.

  • Other interventions — minoxidil, finasteride, spironolactone, microneedling: No pharmacological interaction is known or expected, since keratin is digested to amino acids. Combined use is common; the practical issue is attribution, because concurrent starts make it impossible to tell what worked.

Populations who should avoid Solubilized Keratin:

  • Known allergy to wool, lanolin, poultry or feather protein, or to fish or shellfish where the product also contains marine collagen
  • Phenylketonuria, because free amino-acid keratin hydrolysates deliver unbound phenylalanine
  • Homocystinuria and other inherited sulfur amino acid disorders, including cystathionine beta-synthase deficiency
  • Wilson disease (an inherited disorder of copper accumulation) or any copper-restricted regimen, where copper-containing combination capsules are contraindicated
  • Chronic kidney disease stage 4 or worse (estimated glomerular filtration rate below 30) on a protein-restricted diet, at protein-supplement doses
  • Pregnancy and lactation, and anyone under 18, since every trial excluded these groups and no safety data exist

Risk Mitigation Strategies

  • Separate the product from blood draws: Stop any biotin-containing keratin capsule 48–72 hours before laboratory testing and tell the phlebotomist, to prevent falsely high or low thyroid and cardiac marker results.

  • Choose a keratin-only product where possible: Selecting a single-ingredient solubilized keratin, rather than a multi-nutrient hair, skin and nail capsule, removes the biotin interference and mineral-overload risks entirely.

  • Total the mineral labels before stacking: Add zinc, copper and selenium across every product taken, keeping zinc under 40 mg/day and selenium under 400 µg/day, to avoid copper depletion and selenium-induced shedding.

  • Establish the cause before treating the symptom: Test ferritin, thyroid function and a blood count before starting, so a treatable cause of shedding or brittle nails is not masked for months by gradual cosmetic change.

  • Start at the studied dose, not the highest: Use 500 mg/day for at least 90 days before considering 1000 mg/day; the higher dose added little beyond skin hydration and doubles the amino-acid and cost load.

  • Introduce it alone: Start no other hair, nail or skin intervention for 90 days, so that any change or any adverse effect can be attributed rather than guessed at.

  • Take it with food if digestion is sensitive: Splitting the dose across two meals addresses the mild gastrointestinal intolerance that accounted for the only withdrawals recorded in trials.

  • Confirm source disclosure before purchase: Buying only products that name the source material and carry third-party certification addresses the undisclosed-allergen risk behind the recall of a keratin-collagen product.

Therapeutic Protocol

  • Standard protocol: 500 mg/day of solubilized keratin for 90 days, the dose and duration used in every positive trial. Practitioners in functional and cosmetic dermatology typically continue it as an ongoing supplement rather than a course.

  • Dose-ranging alternative: 1000 mg/day of feather-derived keratin hydrolysate outperformed 500 mg on skin hydration and hair gloss only, with no separation on wrinkles, elasticity or nails (Tursi et al., 2025).

  • Protein-supplement approach: A separate approach uses 0.8 g/kg/day of soluble keratin as a food protein for lean-mass support rather than cosmetics, roughly a hundredfold higher intake (Crum et al., 2018).

  • Competing therapeutic approaches: Conventional dermatology treats hair thinning with minoxidil, finasteride or spironolactone and nail brittleness with biotin. Neither framing is the default here; oral keratin is an adjunct with a weaker but non-empty evidence base.

  • Who popularised each approach: The wool-derived cosmetic protocol originates with Roxlor’s Cynatine programme, the feather-derived one with BCF Life Sciences. Bauman Medical popularised the combined clinical approach, and sells the procedures it recommends.

  • Best time of day: No circadian effect is known or plausible, since keratin is digested as protein. Trials dosed capsules with meals; morning dosing simplifies the 48-hour stop before blood tests.

  • Half-life: Not applicable in the pharmacological sense. Keratin is hydrolysed to amino acids that peak in plasma within roughly 30–120 minutes and are cleared within hours; the clinically relevant timescale is tissue turnover, measured in months.

  • Single versus split dosing: Trials used two capsules daily rather than one, so split dosing is the studied pattern. Splitting also reduces the mild digestive complaints that produced the only trial withdrawals.

  • Genetic polymorphisms: No pharmacogenetic testing applies, since there is no drug-metabolising enzyme involved. Variants worth knowing are cystathionine beta-synthase and MTHFR, a gene whose common variants slow folate handling and shift sulfur amino acid metabolism.

  • Sex differences: Cosmetic dosing evidence comes entirely from women and lean-mass dosing entirely from men. No sex-specific dose adjustment is established, and cross-application of either protocol is an extrapolation.

  • Age considerations: Nail plates grow roughly 3 mm/month at 30 and slower past 60, so a full nail replacement takes 6–12 months in older users. Extending the assessment window past 90 days is reasonable.

  • Baseline biomarkers influencing response: Ferritin, thyroid-stimulating hormone, zinc and total protein intake set the ceiling on response. Correcting a deficiency first is both a better intervention and a cleaner test of the supplement.

  • Pre-existing conditions influencing response: Autoimmune hair loss, scarring alopecia, fungal nail infection and untreated thyroid disease will dominate any keratin effect. Treating these first changes what a 90-day trial of the supplement can show.

Discontinuation & Cycling

  • Lifelong or short-term: Neither is established. The studied unit is a 90-day course; continued use beyond that is a commercial convention rather than an evidence-based one, since no trial ran longer.

  • Withdrawal effects: None reported. Keratin is a food protein with no receptor activity, no dependence potential and no rebound mechanism; no trial recorded any symptom on cessation.

  • Tapering: Not applicable. There is no physiological reason to taper a dietary protein, and no protocol has proposed one.

  • Loss of effect after stopping: Expect gradual regression rather than a rebound. Hair and nail benefits depend on ongoing substrate supply during matrix growth, so gains fade over the following turnover cycle of several months.

  • Cycling for efficacy: No evidence supports cycling. No tolerance, receptor downregulation or diminishing-returns pattern has been described, so the usual rationale for cycling does not apply here.

  • Practical stop rule: If no change in shedding, nail breakage or skin measures is apparent after 90 days at 500 mg/day, continuing is unsupported; the trials that found effects found them within that window.

Sourcing and Quality

  • Source material matters: Products derive from New Zealand sheep wool (the Cynatine lineage) or poultry feathers (the Kera-Diet lineage). These are chemically different preparations with separate trial evidence; the label should name which one it contains.

  • Look for the studied form and dose: The evidence attaches to solubilized or extensively hydrolysed keratin at 500 mg/day. “Keratin” alone on a label, without a solubilization claim and a milligram figure, is not the studied ingredient.

  • Third-party testing: Look for NSF Certified for Sport, United States Pharmacopeia Verified or Informed Choice marks, and for a certificate of analysis covering heavy metals, since wool and feathers concentrate environmental metals.

  • Allergen disclosure: Confirm the source species and check for marine collagen, fish or shellfish in combination products. The one recall on record for a keratin capsule was an undeclared fish allergen, not the keratin itself.

  • Formulation trade-off: Branded blends such as Cynatine HNS add biotin, zinc, copper and B vitamins. That mix carries the trial evidence but also the assay-interference and mineral-stacking risks; single-ingredient keratin avoids both.

  • Reputable suppliers: Roxlor supplies the wool-derived ingredient and BCF Life Sciences the feather-derived one; Life Extension is among the finished-product brands carrying the branded wool-derived complex under a good manufacturing practice programme.

  • No vegan or vegetarian option exists: Keratin is definitionally animal-derived. Products claiming plant keratin contain something else, usually a plant protein hydrolysate with no relationship to the trial evidence.

Practical Considerations

  • Time to effect: Nail and hair shedding changes appeared by day 30 and strengthened through day 90; skin measures moved by day 45. Judging before 90 days at the studied dose is premature.

  • Common pitfall — starting several things at once: Beginning keratin alongside minoxidil, a new shampoo and a multivitamin makes attribution impossible, and is the single most common reason users cannot tell whether it worked.

  • Common pitfall — treating a symptom with an unknown cause: Brittle nails and shedding frequently signal iron deficiency or thyroid disease. Reaching for a supplement first delays a diagnosis that would have produced a larger effect.

  • Common pitfall — forgetting the biotin before blood tests: Users routinely arrive for thyroid or cardiac testing on a biotin-loaded capsule, producing results that are then acted on or repeated unnecessarily.

  • Regulatory status: In the United States it is a dietary supplement under the 1994 Dietary Supplement Health and Education Act, sold without pre-market efficacy or safety review. The European Food Safety Authority has authorised no health claim for keratin.

  • Cost and accessibility: Widely available online and in pharmacies at roughly USD 20–40 per month, which is neither exceptionally expensive nor hard to access, but is recurring and unreimbursed since cosmetic hair and nail care is self-pay.

Interaction with Foundational Habits

  • Sleep: No direct interaction in either direction. Keratin contains no stimulant and no sedating compound, and no trial recorded sleep effects. The indirect link runs the other way: chronic short sleep drives the diffuse shedding that keratin is taken for, so unaddressed sleep debt caps the achievable benefit.

  • Nutrition: Potentiating in one direction, redundant in another. Adequate total protein at 1.2–1.6 g/kg/day already supplies far more cysteine than a 500 mg capsule, so benefit is most plausible on low-protein or restrictive diets. Take it with a meal; iron and zinc-rich foods support the same endpoints.

  • Exercise: Direct but limited. As a protein source keratin increased lean mass over casein in trained cyclists, yet it is low in leucine and lysine, so it is a poor stand-alone muscle protein. It did not blunt or improve endurance performance (Crum et al., 2018).

  • Stress management: Indirect. Keratin has no measured effect on cortisol or the stress response. The relevant mechanism runs from stress to shedding: acute stressors push follicles into the resting phase months before hair falls, so stress reduction addresses a cause the supplement can only partly offset.

Monitoring Protocol & Defining Success

Before starting, the point of baseline testing is to rule out a treatable cause rather than to track keratin itself, since no biomarker responds to the supplement directly. A sensible baseline covers iron stores, thyroid function, a blood count, and the trace minerals that combination products duplicate. Alongside the bloodwork, record a standardised photograph of the hairline and part width, a count of nails currently split or broken, and a note of how much hair is shed on a typical wash day, because these are the endpoints trials actually moved. For ongoing monitoring, repeat the photographs and nail count at 45 and 90 days, recheck thyroid function and ferritin at three months if either was borderline, and then move to a six to twelve month cadence for anyone continuing long term.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Ferritin 70–100 ng/mL Low iron stores independently cause shedding Conventional range starts at 15 ng/mL; ferritin rises with inflammation, so pair with high-sensitivity C-reactive protein (hs-CRP, a general inflammation marker)
Thyroid-stimulating hormone (TSH) 0.5–2.0 mIU/L Both under- and overactive thyroid cause hair and nail change Conventional range extends to 4.5 mIU/L; stop biotin-containing products 48–72 hours before the draw
Free T4 1.0–1.5 ng/dL Confirms thyroid status when TSH is borderline Same biotin washout applies; T4 is thyroxine, the main circulating thyroid hormone
Serum zinc 90–120 µg/dL Deficiency causes shedding; excess from stacking depletes copper Draw fasting and morning; conventional lower bound of 60 µg/dL is too permissive for this purpose
Serum copper 80–100 µg/dL Detects copper depletion caused by stacked zinc Best interpreted as a zinc-to-copper ratio near 8:1 to 12:1 rather than in isolation
Serum selenium 100–140 µg/L Both deficiency and excess cause hair and nail loss Relevant only when several hair, skin and nail products are combined; toxicity presents above roughly 400 µg/L
25-hydroxyvitamin D 40–60 ng/mL Low status is associated with several hair loss patterns Conventional sufficiency threshold is 30 ng/mL; check after three months of any change in dose
Complete blood count Haemoglobin 13.5–15.0 g/dL (women), 14.5–16.0 g/dL (men) Detects anaemia driving diffuse shedding Complete blood count (CBC) is the standard panel of red cell, white cell and platelet measures; pair with ferritin
Plasma homocysteine 6–8 µmol/L Reflects sulfur amino acid handling at protein-supplement doses Conventional cut-off is 15 µmol/L; only relevant above cosmetic dosing or with known sulfur-metabolism variants
Estimated glomerular filtration rate (eGFR) Above 90 mL/min/1.73m² Sets whether a protein-level dose is appropriate eGFR is a calculated measure of kidney filtering capacity; below 30 the protein-supplement approach is contraindicated
Hair pull test No established target value; track change from the individual’s own baseline count The endpoint that trials actually moved Standardise technique, wash-day timing and the same examiner; a 30% or greater reduction matches the trial signal

Qualitative markers worth tracking:

  • Hair shed counted on a fixed wash-day routine, using the same brush and the same interval
  • Number of nails currently split, chipped or broken, counted on the same day of each month
  • Subjective nail hardness and resistance to bending, which was the endpoint trials scored
  • Hair shine and manageability, self-rated on a simple scale and photographed under fixed lighting
  • Skin smoothness and hydration by touch, particularly across the cheeks and around the eyes
  • Digestive comfort in the first two weeks, the window in which the only trial withdrawals occurred

Success is a measurable drop in shed hair count, fewer broken nails, or visible skin change at 90 days, without new symptoms.

Emerging Research

  • Combination capsule trial in thinning hair: A 40-participant trial of a biotin, collagen and keratin complex measuring hair thickness and strength in adults with self-perceived thinning hair, with primary completion in May 2026 (NCT07520019). It will not isolate keratin’s contribution from the other two ingredients.

  • Mechanistic serum-transfer study: A 10-participant study collecting serum after ingestion of a feather-derived keratin hydrolysate and applying it to skin and intestinal cell cultures (NCT06612866). It directly tests the “aminobiotic” signalling claim, and could weaken it if enriched serum behaves like control serum.

  • Keratin biomaterials as a parallel line: A 143-participant trial of wool-derived keratin dressings for venous leg ulcers (NCT02896725), completed in 2019, anchors a topical and wound-care lineage still generating trials. Findings there would strengthen the biological plausibility of keratin as an active material rather than inert protein.

  • The independent replication gap: The decisive open question is whether any non-sponsor group reproduces the cosmetic findings. The largest synthesis to include this ingredient closed by calling for exactly that (Alanazi et al., 2026); until it happens, the effect estimates should be treated as provisional.

  • Comparative supplement rankings could displace it: Network analyses now rank supplements against each other for hair density (Zhou et al., 2025). As keratin enters such comparisons, it may be shown to underperform better-studied options, which would weaken rather than strengthen the case.

  • Sulfur amino acid restriction research cuts the other way: Work on methionine and cysteine restriction as a lifespan lever (Lee et al., 2016) could make routine high-dose sulfur amino acid supplementation look unattractive for a longevity-oriented user, even if the cosmetic findings hold.

Conclusion

Solubilized keratin is the protein of hair, nail and skin, taken apart chemically so the gut can absorb it, and sold mainly as a capsule for hair thickness, nail hardness and skin quality. The human evidence is consistent in direction and modest in size: fewer hairs shed, harder nails, better skin hydration and shallower fine lines over three months, plus a single independent finding of extra lean mass when it is used as a protein rather than a cosmetic. Those numbers are real, but almost all of them come from small, short trials in women that were funded and run by the companies selling the ingredient, and no outside group has yet reproduced them. That conflict of interest is the central limitation of the whole evidence base, and it applies on the clinical side too, where the specialists shaping practice often sell the treatments they compare it against.

Harms recorded so far are minor: occasional digestive upset, allergy to the animal source material, and mineral overload when several similar products are stacked. The most practically important problem is not keratin at all but the biotin packaged with it, which distorts common blood tests. For someone already eating plenty of protein, the amounts involved are small, the effects are cosmetic rather than life-extending, and the honest summary is a plausible, cheap, low-risk option resting on evidence that has not yet been tested by anyone with nothing to gain.

Top - Benefits - Risks - Protocol